UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000023065 |
|---|---|
| Receipt number | R000026585 |
| Scientific Title | An intergroup phase III trial of Ramucirumab plus Irinotecan in third or more line Beyond progression after Ramucirumab for Advanced Gastric cancer. |
| Date of disclosure of the study information | 2016/07/13 |
| Last modified on | 2024/01/29 21:16:58 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2016/07/07 19:58:05 | ||
| 2 | Update | 2016/11/29 22:05:28 | Public title Public title |
|
| 3 | Update | 2017/02/21 18:22:54 | Recruitment status Anticipated trial start date |
|
| 4 | Update | 2017/06/30 20:08:58 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria |
|
| 5 | Update | 2018/07/27 20:16:14 | Recruitment status |
|
| 6 | Update | 2018/07/27 20:17:34 | UMIN ID1 |
|
| 7 | Update | 2021/03/21 11:23:27 | Date of IRB Anticipated trial start date Last follow-up date |
|
| 8 | Update | 2021/08/09 19:03:59 | Last follow-up date Date analysis concluded |
|
| 9 | Update | 2022/07/13 21:09:27 | Last follow-up date Date analysis concluded |
|
| 10 | Update | 2023/01/15 23:03:16 | Recruitment status |
|
| 11 | Update | 2023/01/15 23:07:26 | Number of participants that the trial has enrolled |
|
| 12 | Update | 2024/01/29 21:16:58 | Last follow-up date |
